The Medicines and Healthcare products Regulatory Agency has granted approval for Kerendia (finerenone) for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction of 40% or more in adults in the UK, according to Bayer PLC. The announcement marks a new treatment option for a group of patients living with a long-term condition that can significantly affect daily life.
A new option for patients with chronic heart failure
Bayer said the approval covers adults with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) ≥ 40%. The company described Kerendia as a non-steroidal, selective mineralocorticoid receptor antagonist. The news was reported on 13 April 2026.
Chronic heart failure remains a major clinical challenge because it can limit exercise tolerance, increase breathlessness and require ongoing monitoring and treatment adjustments. The latest approval adds to the range of therapies available to clinicians managing the condition in routine care.
What the approval means in practice
The UK authorisation gives physicians another treatment pathway to consider for appropriate patients with symptomatic heart failure. Bayer framed the decision as an important step for adults in the UK who may benefit from a therapy that can be taken as part of ongoing disease management.
The company’s announcement focused on the regulatory approval itself and did not provide further clinical detail in the material available here. For patients and healthcare teams, the decision is likely to be most relevant in the context of existing heart failure management plans and specialist assessment.
Heart failure remains a high-burden condition
Heart failure is one of the conditions that can place a sustained burden on patients, families and the health system. New medicines that broaden treatment choice are closely watched because they can influence how care is delivered across primary and specialist settings.
In the absence of additional trial data in the source material, the immediate significance of the news is the regulatory milestone itself. The approval indicates that Kerendia has met the standard required for use in the UK for the specified patient group.
For clinicians and patients, the next focus will be how the treatment is incorporated into practice and which adults with symptomatic chronic heart failure are most likely to benefit.
Source: News-Medical CKD latest news page; NICE news
Sursa foto: Imagine generată AI
